NOVO expected to reach ATH during 2026Based on EW count and general knowledge about the company, it is expected that Novo will get back to the top (approx x2 from here) during 2026. Lets see
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
13.20 PLN
57.83 B PLN
166.31 B PLN
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG01VCLYS74
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
NVO Soaring Towards TargetsOur NVO call debit spreads and LEAPS options soaring towards targets at the 233 EMA here.
Beautiful thing when fundamentals, valuations and technicals align.
Impulse move from the bottom gave us a hat trick - triple green tags (white circles) for bullish A+ momentum signals into a consolidation p
NVO bounce off of Ozempic launch AVWAPOzempic launched Feb 5 2018. Anchoring our VWAP to that date we get our confirmation of a strong anchor from the COVID bounce, indicating institutional buying at that level. Over 7 years later, we get another opportunity.
NOVO is looking at a strong bullish bottoming outNYSE:NVO is looking at a strong bullish reversal and is likely to head higher after stochastic shows overbought AND long term stochastic shows clear confirmation of oversold crossover.
Price action shows a clear break out of the downtrend line and with the rounding bottom, the stock is likely to
Novo Nordisk: Massive buying opportunityNovo has been struggling big time, december and march hit especially hard.
American institutions have held large positions in Novo, and this was felt when they had to sell off due to risk management with the looming tariffs.
However, the sheer devaluation & importance of their export, is going to
nvo bullish long Long Setup Idea – Not Financial Advice - AH
This is a long trade setup based on my personal analysis.
The entry, stop-loss, and target levels are outlined for educational and illustrative purposes only.
📈 Entry:
🛑 Stop Loss:
🎯 Target(s):
Disclaimer:
I am not a financial advisor. This idea i
NVO Exhibits High Monthly Volume Amid Downtrend – SHortNVO Exhibits High Monthly Volume Amid Downtrend – Potential Accumulation Phase
📉 Post:
Novo Nordisk (NVO) has experienced a significant decline from its 52-week high of $148.15 to a recent low of $57.00. However, the monthly chart reveals an unusually high trading volume, which may indicate accumul
The most profitable drug known to man. Liquid goldThe title speaks for itself self.
Weekly RSI retesting a 10yr low.
Ozempic (GLP1) is and will continue to be the most profitable drug known to man.
Novo 1h longShould get up and at least break the neckline from the bigger SHS/IHS.
Stop below zone or lower trendline.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Curated watchlists where NVO is featured.
Frequently Asked Questions
The current price of NVO is 280.90 PLN — it hasn't changed in the past 24 hours. Watch NVONORDSK stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange NVONORDSK stocks are traded under the ticker NVO.
NVO stock has fallen by −3.88% compared to the previous week, the month change is a 10.59% rise, over the last year NVONORDSK has showed a 10.59% increase.
We've gathered analysts' opinions on NVONORDSK future price: according to them, NVO price has a max estimate of 515.09 PLN and a min estimate of 200.31 PLN. Watch NVO chart and read a more detailed NVONORDSK stock forecast: see what analysts think of NVONORDSK and suggest that you do with its stocks.
NVO stock is 0.00% volatile and has beta coefficient of 1.42. Track NVONORDSK stock price on the chart and check out the list of the most volatile stocks — is NVONORDSK there?
Today NVONORDSK has the market capitalization of 1.21 T, it has decreased by −5.74% over the last week.
Yes, you can track NVONORDSK financials in yearly and quarterly reports right on TradingView.
NVONORDSK is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NVO earnings for the last quarter are 3.67 PLN per share, whereas the estimation was 3.43 PLN resulting in a 6.95% surprise. The estimated earnings for the next quarter are 3.42 PLN per share. See more details about NVONORDSK earnings.
NVONORDSK revenue for the last quarter amounts to 43.84 B PLN, despite the estimated figure of 43.76 B PLN. In the next quarter, revenue is expected to reach 44.51 B PLN.
NVO net income for the last quarter is 16.30 B PLN, while the quarter before that showed 16.17 B PLN of net income which accounts for 0.83% change. Track more NVONORDSK financial stats to get the full picture.
NVONORDSK dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 21, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NVONORDSK on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NVONORDSK EBITDA is 88.05 B PLN, and current EBITDA margin is 50.95%. See more stats in NVONORDSK financial statements.
Like other stocks, NVO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NVONORDSK stock right from TradingView charts — choose your broker and connect to your account.